Vesalius Therapeutics focuses on developing innovative approaches to treat common diseases, utilizing proprietary patient-derived models to screen drug candidates and identify new therapeutic targets.

Vesalius Therapeutics

Vesalius Therapeutics | 2,231 followers on LinkedIn. Pioneering a revolutionary platform to generate breakthrough treatments for common diseases | Pioneering a revolutionary platform to generate breakthrough treatments for common diseases.

Data Solutions Architect

Nick B.

Senior Vice President and Head of Drug Discovery at Vesalius Therapeutics (formerly Serqet Therapeutics)

Ben Munoz

Talita Turnier

SVP Platform Development, Vesalius Therapeutics | Research leader | Platform development and operation | Data science | Target discovery/validation |…

Chris Cotsapas

Vesalius and GSK share the conviction that targeting the causal factors of common diseases like Parkinson’s disease is the key to developing breakthrough medicines faster and with a higher probability of success. Read more: https://lnkd.in/eSZmP-Vz #ParkinsonsDisease #ParkinsonsAwareness #Biotech #Parkinsons

Exciting news from Flagship Pioneering as they announce the raise of $3.6 billion to fuel breakthrough innovations that transform human health and sustainability. We are proud to be #FlagshipFounded and part of an ecosystem of companies – present and future – taking bold scientific leaps to deliver a better future for all. https://lnkd.in/epadgTVp

Our CEO Christopher Austin describes how Vesalius has developed the first precision platform for common diseases and what’s ahead for the company as its lead candidates approach the clinic.

Our CEO Christopher Austin had a great discussion last week with colleagues at the Flagship Pioneering studio on the opportunities for bioplatforms to dramatically scale the creation of new medicines while also finding novel ways to treat common diseases with a level of precision that was previously reserved for rare diseases. #JPM2024

In Flagship’s 2024 Annual Letter, founder and CEO @Noubar Afeyan reflects on navigating through polycrisis and what it will take to make bigger leaps for patients and the planet including {novel partnerships, continuous innovation, global reach, both forms of AI} Read his annual newsletter here: https://lnkd.in/ez-KuWxi #FlagshipFounded

VESA

COM:VESALIUSTX

Vesalius Therapeutics

locale

market

industry

website

crunchbase

linkedin

investor of

Metrics